Relutrigine

Small molecule

Also known as PRAX-562

Filedunder review

Evidence outlook · regulatory review

Epilepsy: application under FDA review, decision date 2026-12-27

Relutrigine NDA granted priority review (2026-03-30). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Also in development:Developmental and Epileptic Encephalopathies · Phase 3 · under FDA review

Source for the program status

Company guidance: topline data expected fourth quarter of 2026 (NCT07010471; Praxis Precision Medicines, Inc., 9 Nov 2026). “The EMERALD study, which is evaluating relutrigine in patients with broad DEEs, has completed recruitment, with topline results anticipated in the fourth quarter of 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Developmental and Epileptic Encephalopathies
Phase 2/3 (1)
Developmental and Epileptic Encephalopathies
NCT05818553 · Praxis Precision Medicines
2023-08-02 – 2027-03-01 · SCN2A Encephalopathy, SCN8A Encephalopathy
What this study did

Competitive landscape

This drug's own stage for Developmental and Epileptic Encephalopathies: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Relutrigine: this drugPhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
RufinamideApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Relutrigine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3EpilepsyActive not recruiting
Est. primary completion 2026-12 · NCT07010471 · CT.gov ↗

Company guidance: topline data expected fourth quarter of 2026 (Praxis Precision Medicines, Inc., 9 Nov 2026). “The EMERALD study, which is evaluating relutrigine in patients with broad DEEs, has completed recruitment, with topline results anticipated in the fourth quarter of 2026.” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 December 2026FDA action dateRelutrigine NDA PDUFA target action date (extended)
US, FDA · FDA · Source ↗

Recent

30 March 2026Filing acceptedFDA accepts relutrigine NDA for SCN2A and SCN8A DEEs
US, FDA · Praxis Precision Medicines, Inc. · Source ↗
30 March 2026Priority reviewRelutrigine NDA granted priority review
US, FDA · FDA · Source ↗